Compare Avantis US Small Cap Value ETF (AVUV) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avantis US Small Cap Value ETF vs Johnson & Johnson — how do they compare? Avantis US Small Cap Value ETF trades at $127.59, while Johnson & Johnson trades at $261.24 (market cap $626.09B). The key difference: Johnson & Johnson pays a 2.06% dividend while Avantis US Small Cap Value ETF pays none. Which is the better fit depends on your goals.
| AVUV | JNJ | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $128.74 | $267.24 |
52-Week Low | $93.93 | $172.78 |
Market Cap | — | $626.09B |
Volume | — | 6,156,228 |
Enterprise Value | — | $654.37B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVUV trades at $127.50, up 0.39% with a bullish technical outlook supported by moving averages. The small-cap value ETF is benefiting from strong sector performance, with the Russell 2000 up approximately 20% year-to-date according to 24/7 Wall Street (July 17, 2026). Recent dividend activity includes a $0.44 distribution scheduled for June 2026.
The outlook remains positive as small-cap value continues outperforming growth stocks, with AVUV capturing this premium. Key risks include interest rate sensitivity and regional bank exposure, while institutional sentiment appears favorable given the ETF's role in diversifying tech-heavy portfolios.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Avantis US Small Cap Value ETF
AVUV is an actively managed ETF that targets small-cap value companies in the United States. It uses a systematic, rules-based process to identify firms with low valuations and high profitability, aiming to capture the historical premiums of 'size' and 'value' while filtering for financial quality.
Read more on AVUV →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
